← Eichor
Condition: Cd19 Car T Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd19 Car T Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymph
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04484012Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
EARLY_Phase 1 · 1 location(s) · He Huang · NCT06120166Polymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
Phase 2 · 1 location(s) · Daihong Liu · NCT07321301A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT07239323Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
Phase N/A · 1 location(s) · Fudan University · NCT07236203CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Re
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07241468Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases
EARLY_Phase 1 · 1 location(s) · Juventas Cell Therapy Ltd. · NCT06316791UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
EARLY_Phase 1 · 1 location(s) · The Second Hospital of Anhui Medical University · NCT07530380Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed
Phase 2 · 6 location(s) · Academic and Community Cancer Research United · NCT06238648Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07359014CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Phase 1 · 1 location(s) · Michael Randall · NCT06522932CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
Phase 2 · 1 location(s) · Zhejiang University · NCT04661020A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Phase 2 · 1 location(s) · Liping Dou · NCT07587840Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Phase N/A · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07524816A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
Phase 2 · 51 location(s) · Miltenyi Biomedicine GmbH · NCT04844866Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06569472A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory
NA · 3 location(s) · Liang Zou · NCT07490951A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Phase 1/Phase 2 · 9 location(s) · Juventas Cell Therapy Ltd. · NCT05667506Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Ly
NA · 7 location(s) · Mayo Clinic · NCT06630104Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma
Phase 1/Phase 2 · 5 location(s) · Pell Bio-Med Technology Co., Ltd. · NCT05326243CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.